Innate Pharma SA
Justine Galluso is an R&D Associate specializing in Immuno-Oncology at Innate Pharma since July 2021. Prior to this role, Justine worked as an Ingénieur d'études at CIML from September 2016 to July 2021 and completed a stage de fin d’études at APHM, focusing on the disruption of GNAS methylation in human somatotropinomas. Justine holds a Master de Génomique from Aix-Marseille University (2014-2016), a Licence de Biologie Moléculaire et Cellulaire from the University of Montpellier (2013-2014), and a DUT Génie Biologique from IUT Toulon La Garde (2011-2013).
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.